Dual targeting of DNA damage repair pathway by BET and CDK4/6 inhibitors synergistically inhibits breast cancer

被引：0
|
作者：
Chi, S. [1 ]
Wei, F. [1 ]
Fang, Y. [1 ]
Hu, Y. [1 ,2 ]
Duan, W. [1 ,2 ]
Ding, J. [1 ,2 ]
Chen, Y. [1 ,2 ]
机构：
[1] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China
[2] Shandong Lab Yantai Drug Discovery, Bohai Rim Adv Res Inst Drug Discovery, Yantai, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114732
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB202
引用
收藏
页码：S83 / S83
页数：1
相关论文
共 50 条
  • [1] BET inhibitor and CDK4/6 inhibitor synergistically inhibit breast cancer by suppressing BRD4 stability and DNA damage repair
    Chi, Shuaishuai
    Wei, Fan
    Li, Yangsha
    Yu, Lei
    Ma, Chuyao
    Fang, Yanfen
    Yang, Biyu
    Chen, Yi
    Ding, Jian
    TRANSLATIONAL ONCOLOGY, 2025, 51
  • [2] Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
    Piezzo, Michela
    Cocco, Stefania
    Caputo, Roberta
    Cianniello, Daniela
    Di Gioia, Germira
    Di Lauro, Vincenzo
    Fusco, Giuseppina
    Martinelli, Claudia
    Nuzzo, Francesco
    Pensabene, Matilde
    De Laurentiis, Michelino
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (18) : 1 - 23
  • [3] Targeting CDK4/6 in breast cancer
    Shanabag, Anusha
    Armand, Jessica
    Son, Eugene
    Yang, Hee Won
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2025, 57 (02): : 312 - 322
  • [4] CDK4/6 inhibitors in breast cancer
    Dukelow, Tim
    Kishan, Divya
    Khasraw, Mustafa
    Murphy, Conleth G.
    ANTI-CANCER DRUGS, 2015, 26 (08) : 797 - 806
  • [5] The Role of CDK4/6 Inhibitors in Breast Cancer
    Murphy, Conleth G.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (06)
  • [6] Update on CDK4/6 Inhibitors in Breast Cancer
    Tolaney, Sara M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (06) : 298 - 300
  • [7] The Role of CDK4/6 Inhibitors in Breast Cancer
    Conleth G. Murphy
    Current Treatment Options in Oncology, 2019, 20
  • [8] CDK4/6 inhibitors in luminal breast cancer
    Gnant, Michael
    Steger, Guenther G.
    Bartsch, Rupert
    LANCET ONCOLOGY, 2015, 16 (01): : 2 - 3
  • [9] Overcoming resistance to inhibitors of CDK4/6 and BET in estrogen receptor-positive breast cancer
    Cosin, Marc
    Tian, Tian
    Oliveros, Winona
    Kharenko, Olesya A.
    van der Horst, Edward H.
    Patel, Reena G.
    Calosing, Cyrus
    Campeau, Eric
    Jahagirdar, Ravi
    Lakhotia, Sanjay
    Mele, Marta
    Palafox, Marta
    Arribas, Joaquin
    Oliveira, Mafalda
    Saura, Cristina
    Serra, Violeta
    Peiro, Sandra
    CANCER RESEARCH, 2020, 80 (16)
  • [10] Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis
    Huang, Zhi
    Zhao, Borui
    Qin, Zhongxiang
    Li, Yongtao
    Wang, Tianqi
    Zhou, Wei
    Zheng, Jianyu
    Yang, Shengyong
    Shi, Yi
    Fan, Yan
    Xiang, Rong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 181
12345